Teijin Ltd (3401):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12373
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.

Teijin Ltd (3401) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Licensing Agreements 18
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Debt Offering 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Acquisition 27
Teijin Acquires 10% Stake In Kyorin For US$197 Million 27
Teijin Ltd – Key Competitors 28
Teijin Ltd – Key Employees 29
Teijin Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 33
Recent Developments 34
Financial Announcements 34
May 09, 2018: Teijin: Consolidated Financial Statements Summary For the year ended March 31, 2018 34
May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37
Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Teijin Acquires 10% Stake In Kyorin For US$197 Million 27
Teijin Ltd, Key Competitors 28
Teijin Ltd, Key Employees 29
Teijin Ltd, Other Locations 31
Teijin Ltd, Subsidiaries 31
Teijin Ltd, Joint Venture 33

List of Figures
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Teijin Ltd (3401):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Zuger Kantonalbank AG:企業の戦略・SWOT・財務分析
    Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report Summary Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Information Analysis Inc (IAIC):企業の財務・戦略的SWOT分析
    Summary Information Analysis Inc (IAI) is a technology company that offers technical solutions. The company offers IT services such as legacy mainframe modernization, database conversion and migration, electronic forms conversion, ebusiness and web based solutions, integrated tablet and mobile appli …
  • Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析
    Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • National Autonomous University of Mexico:企業の戦略的SWOT分析
    National Autonomous University of Mexico - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Exonate Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs, which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The company’s alternative mRNA splicing is modulated in disease states that results in the pathologic …
  • Ei Towers SpA:企業の戦略・SWOT・財務情報
    Ei Towers SpA - Strategy, SWOT and Corporate Finance Report Summary Ei Towers SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • FirstGroup plc (FGP):企業の財務・戦略的SWOT分析
    FirstGroup plc (FGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • MarkWest Energy Partners LP:企業のM&A・事業提携・投資動向
    MarkWest Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MarkWest Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Kuraray Co Ltd (3405):企業の財務・戦略的SWOT分析
    Kuraray Co Ltd (3405) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • Inner Mongolia Yili Industrial Group Co Ltd:企業の戦略・SWOT・財務分析
    Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Coffee Republic Trading Ltd:企業の戦略・SWOT・財務分析
    Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report Summary Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Oriental Yeast Co Ltd:企業の戦略・SWOT・財務情報
    Oriental Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Oriental Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Natural Resource Partners L.P.:企業のM&A・事業提携・投資動向
    Natural Resource Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Natural Resource Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Volkswagen AG (VOW3)-エネルギー分野:企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • Circassia Pharmaceuticals Plc (CIR)-医療機器分野:企業M&A・提携分析
    Summary Circassia Pharmaceuticals plc (Circassia) develops treatments for allergy and respiratory diseases such as asthma. The company’s product line includes NIOX, which is used to improve asthma management by assisting in diagnosis. In addition, the company's pipeline includes a number of inhaled …
  • Qantas Airways Ltd (QAN):企業の財務・戦略的SWOT分析
    Qantas Airways Ltd (QAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sinclair Broadcast Group, Inc.:企業のM&A・事業提携・投資動向
    Sinclair Broadcast Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sinclair Broadcast Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • StealthGas Inc (GASS):石油・ガス:M&Aディール及び事業提携情報
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆